DJIA 17,407.21 -271.49 -1.54%
NASDAQ 4,693.22 -78.54 -1.65%
S&P 500 2,033.67 -23.42 -1.14%
market minute promo

Exelixis (NASDAQ: EXEL)

1.75 0.03 (1.74%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

EXEL $1.75 1.74%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $1.73
Previous Close $1.72
Daily Range $1.71 - $1.73
52-Week Range $1.26 - $7.64
Market Cap $341.6M
P/E Ratio -1.17
Dividend (Yield) $0.00 (0.0%)
Volume 52,996
Average Daily Volume 2,746,356
Current FY EPS -$1.41





Exelixis (EXEL) Description

A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. Website:

News & Commentary

This Popular Beverage Could Be Responsible For a 20% Reduction in Melanoma Risk

The good news: this beverage reduced the risk of an aggressive form of skin cancer by 20% in a very large study. The better news: 83% of you are already consuming this beverage on a daily basis!

Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 4

The Surprising Thing Most of 2014's Top 10 Stocks Have in Common

8 out of 10 of last year's best-performing stocks have this one important common denominator.

Exelixis (EXEL) Is Today's Strong On High Volume Stock

Update: My Take On Exelixis' New Agreement With Sobi To Provide COMETRIQ In Europe

3 Biotech Stocks That Could Trounce Gilead Sciences, Inc. in 2015

Gilead Sciences may look cheap, but three of our top analysts believe these three other biotech stocks could have an even better 2015.

Does This Drug Offer Exelixis Inc. Investors Hope for the Future?

A potential approval of Exelixis' cobimetinib in 2015 could help restore investors' confidence -- but risk remains.

19 Lesser-Known Biotech Stocks With Robust Drug Pipelines

3 Biotech Stocks That Could Double in 2015

Three Motley Fool contributors tell us which biotech stocks they think could make a big move next year.

5-year lows: Synta Pharmaceuticals Inc, Exelixis Inc, Entropic Communications Inc, and ...

See More EXEL News...

EXEL's Top Competitors

EXEL $1.75 (1.74%)
Current stock: EXEL
TMO $125.53 (-0.09%)
Current stock: TMO
ILMN $200.15 (-0.76%)
Current stock: ILMN
WAT $120.06 (3.40%)
Current stock: WAT